This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus
by Benjamin Rains
AbbVie (ABBV) stock popped on Tuesday. This is part of the global pharmaceutical giant's larger 20% surge in the last week as the market tries to mount a comeback amid the coronavirus uncertainty...
The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children
by Zacks Equity Research
The FDA approves Eli Lilly's (LLY) sBLA for Taltz injection to treat pediatric patients with moderate to severe plaque psoriasis. Stock up.
Top Ranked Income Stocks to Buy for March 31st
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 31st.
COVID-19 Claiming Lives But Therapeutics Could Be on the Way
by Sejuti Banerjea
The WHO's Solidarity testing project could be good news for the world.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - March 30, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia
by Zacks Equity Research
The FDA approves Bristol Myers' (BMY) Zeposia for the treatment of adults with relapsing forms of multiple sclerosis.
Will Rescue Deal Impact Last? 4 Coronavirus-Proof Dividend Picks
by Urmimala Biswas
With the ongoing erratic movement of most stocks, it's a prudent idea for investors to go for dividend-paying stocks as a regular source of income.
Top Ranked Income Stocks to Buy for March 27th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 27th
AstraZeneca's Lokelma Gets Approval in Japan for Hyperkalaemia
by Zacks Equity Research
The Japanese regulatory body nods to AstraZeneca's (AZN) Lokelma for addressing patients with hyperkalaemia. The company collaborates with Silence Therapeutics for siRNA therapeutics.
Top Ranked Income Stocks to Buy for March 26th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 26th.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $67.91, moving +0.62% from the previous trading session.
Coronavirus Drug Development Race to Boost These 4 Stocks
by Zacks Equity Research
Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.
CytomX & Astellas Collaborate to Develop Novel Cancer Therapy
by Zacks Equity Research
CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.
The Extreme Risks of Trading Your Own Retirement Assets - March 25, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - March 24, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
AbbVie's Venclexta Combo Meets Endpoints in Leukemia Study
by Zacks Equity Research
AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with azacitidine, achieves statistically significant improvement in overall survival and composite complete remission rate in treatment-naive AML patients.
Roche Gets FDA Approval for Actemra Trials in COVID-19
by Zacks Equity Research
Roche (RHHBY) gets FDA nod to evaluate Actemra plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia.
Powerful Proof Anyone Can Invest for an Early Retirement - March 24, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Top Ranked Income Stocks to Buy for March 24th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 24th.
Is AbbVie a Good Stock to Buy Amid Coronavirus Uncertainty?
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are off to a strong start.
The Zacks Analyst Blog Highlights: Macy's, AbbVie, Pfizer and New Residential Investment
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Macy's, AbbVie, Pfizer and New Residential Investment
4 Dividend Stocks to Buy Amid the Coronavirus Rout
by Nitish Marwah
The coronavirus has dealt a huge blow to markets globally. Valuations have gone for a toss across every asset class and sector.
AbbVie Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
AbbVie has been struggling lately, but the selling pressure may be coming to an end soon.
Is AbbVie (ABBV) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
AbbVie (ABBV) could produce exceptional returns because of its solid growth attributes.